Abstract Substantial clinical variability is observed in many Mendelian diseases, so that patients with the same mutation may develop a very severe form of disease, a mild form or show no symptoms at all. Among the factors that may explain these diVerences in disease expression are modiWer genes. In this paper, we review the diVerent strategies that can be used to identify modiWer genes and explain their advantages and limitations. We focus mainly on the statistical aspects but illustrate our points with a variety of examples from the literature.
Introduction
Genetic factors can play extremely diverse roles in the etiology of human diseases. A single rare mutation can fully account for a monogenic Mendelian disease, while a set of numerous genetic and environmental factors can be involved in a multifactorial disease. Huge clinical variability can be observed even for simply determined diseases, and this variability may itself involve genetic factors, the so-called modiWer genes.
The modiWer gene concept is not new, having been introduced in 1941 by Haldane (1941) . It may be useful to review its deWnition, which varies from one study to another. Here are some deWnitions found in literature:
1. "A gene that is recognized by its alteration of the phenotypic expression of genes at one or more other loci" (Futuyma 1998 ) 2. "A gene that alters the expression of a gene at another locus" (Hall and Horton 1997) 3. "A gene that aVects the phenotypic expression of another gene" (Suzuki et al. 2004 ) 4. "A gene capable of modifying the manifestation of a mutant gene without having an obvious eVect on the normal condition" (Grüneberg 1963 ).
The variety of interpretations to which these deWnitions lend themselves highlights the vagueness of the concept. Some studies also refer to these situations as digenic or oligogenic inheritance models, depending on the number of genes involved (Nadeau 2001; Slavotinek and Biesecker 2003) . In our view, the diVerence between modiWer genes and oligogenicity lies in the deWnition of the phenotype. A good example is coat color in mice [for a review see (Silvers 1979) ]: color is controlled by gene B but its intensity (full or diluted) depends on gene D. If the phenotype is deWned in three classes, as white, gray, and black, it can be explained by a digenic inheritance model. If instead we consider that the primary phenotype is white or black (unaVected/aVected), we Wnd diVerences in intensity among the mice with the black phenotype (full black or gray) and gene D, which controls intensity, is a modiWer gene. Searching for modiWer genes is diVerent from searching for the gene(s) responsible for the disease. The diVerences are in the phenotype to be explained and in the study population. When genes involved in the disease are sought, the phenotype of individuals is usually deWned as aVected or unaVected whereas for modiWer genes, the phenotype of interest must be a measure of the clinical variability in the population of aVected individuals (the disease phenotype versus a clinical phenotype). The diVerence may appear subtle, especially if the goal is to Wnd the genes that explain the lack of penetrance of a given mutation, for then disease and clinical phenotypes may be the same. Even in this case, however, the population under study diVers, for it is restricted to the population of individuals who carry mutations known to be involved in the disease.
Many arguments support the concept of modiWer genes and numerous studies have identiWed such genes in mice. A traditional example is multiple intestinal neoplasia. In mice, the disease is due to a dominant mutation of the Apc gene, but the number of intestinal tumors is controlled by the Mom-1 (ModiWer of Min-1) gene (Dietrich et al. 1993 ). In humans, modiWer genes are often suggested to explain clinical variability in monogenic diseases (Feingold 2000; Nadeau 2001; Wolf 1997) , but very few modiWer genes have been identiWed so far and the mechanisms underlying clinical variability remain poorly understood, probably because of the involvement of complex mechanisms and multiple factors.
Identifying these genetic modiWers may be of great interest from the viewpoints of both treatment and genetic counselling (Lyonnet et al. 2003) , but it remains very challenging, despite the powerful genetic tools available today. In this paper, we describe possible strategies to identify modiWer genes, strategies that appear very similar to those used to study multifactorial diseases, but with additional speciWcities and problems.
Choice of clinical phenotypes and study populations
The Wrst and probably the most important steps in the study of modiWer genes are to deWne the clinical phenotype for which one seeks modiWer genes and to choose the study population.
DeWnition of the clinical phenotype
The clinical phenotype may be qualitative. Examples include the presence or absence of meconial ileus in cystic Wbrosis, the presence or absence of Hirschsprung's disease in Ondine's curse, the presence or absence of scoliosis in neuroWbromatosis, and the four severity classes of spinal muscular atrophy. Alternatively it may be quantitative, such as age at onset in Friedreich's ataxia or Huntington's disease, survival time in hypertrophic cardiomyopathy, or forced expiratory volume value in 1 s (FEV 1 ) in cystic Wbrosis. Choosing a relevant clinical phenotype may be diYcult, and adjustment for appropriate covariables (such as age and sex) is often necessary. For example, in studying hypertrophic cardiomyopathy, one may be interested in maximal wall thickness (MWT), interventricular septum thickness (IVS) or, as proposed by Spirito and Marron (1990) , a score combining several measurements of left ventricular hypertrophy (LVH score). All these variables must be adjusted for appropriate covariates, such as age, sex and body surface area (Forissier et al. 2005) . Success in Wnding genetic factors may depend on the choice of variable and on the inclusion of appropriate covariates in the model. The study by Milet et al. (2007) of serum ferritin levels in hereditary hemochromatosis illustrates this point: the eVect of one SNP in the bone morphogenetic protein 2 (BMP-2) gene was signiWcant after adjustment for age and sex (nominal P < 0.0001 and P < 0.0075 after correction for 75 tests) and was only borderline without any such adjustment (nominal P = 0.0007 and P = 0.053 after correction for 75 tests) (J. Milet, personal communication) . Another interesting illustration is the study of the incidence of ischemic disease in familial hypercholesterolemia and xanthomatosis where the diVerences observed between men and women disappeared after adjustment for smoking habits (Beaumont et al. 1976 ). The choice of phenotype is also diYcult when looking for modiWer genes that may be involved in lung disease severity in cystic Wbrosis patients. Most studies use empirical Bayes estimates of FEV 1 (% predicted) at age 20, rather than crude FEV 1 , because this age has been shown to be best for distinguishing between patients with mild and severe disease (Schluchter et al. 2006) .
A good description of the phenotypic variability in the study population is often required and might also pose some problems as these patients are usually not randomly ascertained. They are more likely sampled if they belong to a family with several disease cases and it might be necessary to account for this ascertainment bias using methods such as the ones described in Carayol et al. (Carayol and Bonaiti-Pellie 2004) .
DeWnition of the study population
The population of individuals to be studied must also be deWned. Depending on the disease, one might focus on individuals with a given mutation known to be involved in the monogenic disease. For example, the study of the modiWer genes involved in diVerent phenotypes associated with cystic Wbrosis is usually performed in the subpopulation of individuals homozygous for the F508del mutation of the CFTR gene. This restriction on a given mutation is possible however only for monogenic disease where one major mutation accounts for a large proportion of the cases. In many instances, this condition cannot be met and investigators must consider the population of patients with any of the mutations known to be involved in the disease.
Evidence for the role of genetic factors in the variability of disease expression
Several factors other than modiWer genes, such as environmental factors, might explain disease expression variability. Before planning the search for genetic factors, it is thus important to verify that these other factors do not explain all the variability in disease expression and to assess the evidence for a genetic control of the clinical phenotype.
For this purpose, the Wrst step is to show the role of familial factors by comparing the correlation of the clinical phenotype in related and unrelated patients. If genetic factors play a role, inter-family variability should be greater than intra-family variability. This is often diYcult to study especially for rare monogenic diseases. Even for more common diseases such as cystic Wbrosis (CF), the task is not necessarily easy since genetic counselling and prenatal diagnosis have considerably reduced the number of families with multiple aVected individuals. A recently published article by Vanscoy et al. (2007) collected data about the severity of lung disease in 231 sibling pairs aVected by CF. This was possible only through a huge project, the "CF twin and sibling study," which involves 71 CF care centers throughout the United States.
Collection of data on twins can be especially useful in showing that genetic factors are included among these familial factors and in obtaining estimates of the heritability associated with the clinical phenotype. Indeed, twins are usually considered to share the same environment independently of their zygosity. Therefore; if monozygotic twins (MZ) are more similar than dizygotic twins (DZ) for the clinical phenotype, this should be explained by the eVect of genetic modiWers on the clinical phenotype. As an illustration, Vanscoy et al. (2007) studied both MZ and DZ CF twins and concluded that modiWer genes are likely to be involved in several lung disease phenotypes. They provided estimates of the heritability of diVerent lung function measures that ranged from 0.54 to 1.00.
Another way of demonstrating the role of genetic factors in disease expression variability is to take advantage of particular population contexts, as in the study of the age of onset of Huntington's disease (HD) in Venezuelan kindreds (Wexler et al. 2004) , the largest and best characterized HD population in the world (Okun and Thommi 2004) . Most aVected individuals are descendents of one woman who lived in the early nineteenth century in a stilt village on Lake Maracaibo, died from HD and passed her abnormal allele through ten generations.
DiVerent genetic models to explain disease clinical expression variability
As for the genetic models underlying disease susceptibility, there is not a single genetic model explaining the variability of disease clinical expression as illustrated by diVerent examples from the literature. To help decide on the best strategy to identify the genetic factors, it is important to try to determine the most likely model for the studied clinical phenotype.
Genetic heterogeneity of the primary factor involved in the disease A Wrst explanation could be in the existence of some genetic heterogeneity. This heterogeneity may either be at the gene level, with diVerent genes involved in the diVerent sub-entities of the disease, or at the mutation level, with diVerent mutations of the same gene leading to diVerent phenotypic expression of the disease. One major example of genetic heterogeneity is hypertrophic cardiomyopathy, an autosomal dominant disease that can be due to more than 300 diVerent mutations, most of them (»65%) located in two genes encoding the sarcomeric proteins MyBPC3 and Myh7. Survival time is longer for patients with an MyBPC3 mutation than for those with an Myh7 mutation (Charron et al. 2002; Richard et al. 2003) . However, heterogeneity at the mutation level might also inXuence survival time, as shown by Watkins et al. (1992) for mutations in Myh7.
Breast and ovarian cancers furnish another example. Breast cancer can be caused by mutations in the BRCA1 or the BRCA2 genes. BRCA2 mutation carriers are at greater risk of developing ovarian cancer, but this risk also depends on the position of the mutation in these genes: in the BRCA1 gene, the risk is smaller when the mutation is in exons 13-24 (Shattuck-Eidens et al. 1995) and in the BRCA2 gene, the risk is greater when the mutation is at the 3Јend of the gene, compared with the 5Јregion (Gayther et al. 1997 ). Another example is cystic Wbrosis, where pancreatic insuYciency is usually observed in patients homozygous for severe mutations of the CFTR gene (class I, II or III mutations).
The age of onset in HD is also an interesting example. HD is caused by an autosomal dominant expanded triplet (CAG) repeat, located in the huntingtin gene on chromosome 4p16.3. Alleles with more than 40 CAG repeats are considered fully penetrant, but there are diVerences in the age of onset of motor symptoms depending on the speciWc CAG count: a higher number of repeats is associated with earlier onset.
Verifying that genetic heterogeneity does not explain all the clinical phenotype variability is an important step, because this issue may have implications for which patients should be studied and speciWcally, whether the study should be limited to patients who do or do not carry a given mutation. It can also help guide the choice of the clinical phenotype to be studied. A good example is the study of Wexler et al. (2004) on the age of onset in HD. Using 443 HD patients with CAG repeats ranging from 40 to 86. The authors found that the length of the repeat accounted for 72% of the variability in age of onset and that the remaining variability could be explained by the eVect of some genetic factors. To study these genetic modiWers, an appropriate phenotype is thus the residual age of onset after accounting for the contribution of the CAG repeat lengths.
EVect of another variant in the gene in cis or trans position
Phenotypic variability might also be due to the eVect of another variant in the gene, in either the trans or cis position to the primary mutation. In some dominant diseases, clinical expression may depend on the normal allele (trans eVect). Good examples are erythropoietic protoporphyria, where a low expressed allelic variant of the ferrochelatase gene located in trans from the mutation explains the variability in disease expression (Gouya et al. 1996 (Gouya et al. , 1999 (Gouya et al. , 2006 and hereditary elliptocytosis, where the LELY allele increases mutation expression when it is located in trans position to the mutation (Delaunay et al. 1995) . Alternatively, cis eVects might be suspected when the haplotype carrying the disease mutation varies with the clinical phenotype. A striking example is that of Creutzfeldt-Jakob and familial fatal insomnia: carriers of a single mutation in codon 128 of the prion protein gene located on chromosome 20 develop one or the other disease depending on a polymorphism at codon 129 of the same gene that codes for two diVerent amino acids-valine or methionine (Goldfarb et al. 1992 ).
ModiWer genes of disease expression
Disease expression variability might also be explained by the eVect of genes other than the primary one involved in the disease, and it is these that are usually referred to as modiWer genes. Their eVect on disease expression may vary from strong eVects under a "monogenic-like" model to much milder eVects under a "multifactorial-like" model.
Under the "monogenic-like" model, a single modiWer gene exhibits rare fully or almost fully penetrant mutations that explain all or a very important part of the variability in disease expression. Examples of this type of modiWer genes can be found among the genes involved in the splicing machinery [see the recent review of Wang and Cooper (2007) ]. In this case however, the modiWer genes are located close to the primary gene and act with cis eVects.
Another interesting example is the one of autosomal recessive spinal muscular atrophy due to the homozygous deletion of the SMN1 gene but for which some SMN1-deleted individuals are unaVected. A recent article suggests that the Plastin 3 gene may be involved as SMN1-deleted individuals exhibit signiWcantly higher expression of plastin 3 than their SMA-aVected counterparts (Oprea et al. 2008 ). This situation of modiWer gene acting under a "monogenic-like" model is also often described as digenic or oligogenic inheritance. As discussed earlier, this is probably due to the fact that the disease and clinical phenotypes are not well described and a good illustration is Bardet-Bield syndrome (Burghes et al. 2001; Katsanis et al. 2001) .
Under the "multifactorial-like" model, disease expression depends on the eVects of several genetic variants located in diVerent modiWer genes that, by themselves, only explain a small proportion of the variability but interact both with one another and with environmental factors. An example is the eVect of variants of the Melanocortin-1 Receptor gene on the penetrances of CDKN2A germline mutations in Melanoma (Chaudru et al. 2005 ). Another illustration is syndromic Hirschprung's disease in Ondine syndrome where a hypormorphic allele of the RET gene is found to act as a modiWer gene of PHOX2B (de Pontual et al. 2006) . A last example is the one of disease severity in recessive dystrophic epidermolysis Bullosa: the disease is due to mutations in the COL7A1 gene encoding type VII collagen but a frequent functional SNP in the MMP1 promoter was found associated with a higher severity (Titeux et al. 2008) .
It is diYcult to know a priori which of these diVerent models explain the clinical phenotype we are interested in. Familial data might help discriminate between these diVerent models since the expected pattern of clinical resemblance among aVected relatives depends on the genetic model (see Table 1 ). A segregation analysis would also ideally be performed in order to determine how genetic factors play a role in the clinical phenotype. Segregation analysis consists in studying the familial transmission of the clinical phenotype to seek if one gene transmitted in a Mendelian fashion (often referred to as major gene) could explain the data and to determine the most likely mode of inheritance (dominant, recessive etc.). Since the familial data required to perform these diVerent studies are very rarely available, this step is often shunted and investigators move directly to the step of searching for the genetic factors involved in the clinical phenotype with no clue on their number, if any, and nature.
Strategies to identify genetic modiWers
Strategies used to show the role of genetic factors in phenotypic expression are often classiWed into two categories depending on the type of data available: linkage studies and association studies. Another distinction often made is based on the approach, which can be either a systematic approach where the whole genome is scanned or a more focussed approach, where candidate genes or candidate pathways are selected.
Linkage analysis
If family data are available, one may consider performing a linkage analysis by following the segregation of the clinical phenotype and of markers in families. Linkage analysis is usually performed with random markers spanning the whole genome in a systematic approach. Until recently, maps of »400 microsatellite markers were used but nowadays panel of »6,000 single nucleotide polymorphisms (SNPs) are also proposed that ensure a better coverage of the genome.
If a segregation analysis has been performed prior to the genetic screening and the eVect of a major gene could be suspected (monogenic-like model) then a model-dependent linkage analysis could be performed using the parameters of the model estimated in the segregation analysis. If the genetic control of the clinical phenotype is suspected to be more of a multifactorial-like model, then model-free linkage analyses should be used. These studies are usually performed using data on sibpairs.
If the clinical phenotype is qualitative (presence/absence of a trait), three types of sibpairs can be distinguished: sibpairs where both sibs have the trait, sibpairs where both sibs do not have the trait and discordant sibpairs where one sib has the trait and the other does not have it. Note that all these sibs should also be carrier of the primary mutation involved in the disease. Such a linkage strategy was used to search for genetic factors involved in meconium ileus in CF patients. Zielenski et al. (1999) studied a sample of 152 CF aVected F508del homozygous carrier sibpairs. The distribution of aVected sibpairs sharing 2, 1 and 0 alleles identical by descent observed in the 19q13 region diVered according to whether both sibs had meconium ileus. A strong departure from the expected proportions of ¼, ½ and ¼ was observed, especially in the sibpairs discordant for meconium ileus (see Table 2 ). On average they shared fewer alleles identical by descent than expected. This example illustrates that there exist situations for which the use of discordant sibpairs may greatly increase the power of linkage detection. Computing power under various genetic models, Houlston and Tomlinson (1998) showed that the power to detect linkage could be considerably increased by using phenotypically discordant sibpairs, compared with (Li et al. 2003) . A genome-wide scan of 629 aVected sibpairs from 295 families used a variance component approach to age at onset, adjusted for the number of CAG repeats. It found evidence suggestive of linkage (LOD¸2.19) with two regions of chromosome 6 (6p21-23 and 6q24-26). A more recent study by the same group of 102 additional sibpairs conWrmed the linkage with the 6q region (Li et al. 2006 ) with a LOD of 4.94 on the combined sample of more than 700 sibpairs. These results were also conWrmed by a linkage genome-wide scan performed on the Venezualan kindreds using 5,858 SNPs and in which two additional regions of linkage were also identiWed on chromosome 2 (Gayan et al. 2008) . Methods other than variance component that can also be used to search for linkage with quantitative phenotypes include Haseman-Elston regression and Bayesian methods (for a review, see (Feingold 2001)). It is also possible to dichotomize the quantitative phenotype, and then use the same methods as for qualitative phenotypes. The choice of the optimal cutoV point for dichotomization is not necessarily easy, however, and methods to optimize this point should be considered such as the ordered subset analysis (OSA) method (Hauser et al. 2004 ). The idea of this method is to use the information on a quantitative covariate to rank aVected sibpairs in subsets of increasing size where linkage is tested with the disease. It was presented as a method to test for linkage in the presence of genetic heterogeneity but it can also be useful for determining the role of modiWer genes in Mendelian diseases.
Association studies
An alternative strategy to linkage consists in testing for association with the clinical phenotype in samples of individuals who carry the primary mutation involved in the disease. This is the most widely used strategy in the search for modiWer genes involved in CF-associated lung disease. For qualitative clinical phenotypes, the distribution of marker genotypes is compared in patients with and without the clinical phenotype to detect markers that show diVerences. These may be involved in phenotype expression or associated (in linkage disequilibrium) with loci involved in phenotype expression. For quantitative clinical phenotypes, the average value of the phenotype for the diVerent genotypes can be compared with ANOVA or t-tests. Depending on the clinical phenotype and on the model underlying the eVect of the modiWer gene on the phenotype, power may be increased by dichotomizing the trait (Fardo et al. 2007) . As in linkage studies, however, the choice of the appropriate cutoV point might not be easy, and methods that rank cases based on their quantitative trait value should be considered (Macgregor et al. 2006) .
The major limitation of population-based association tests is the well-known issue of population admixture. This problem is often ignored in the study of modiWer genes although it is probably even more acute than in the search for susceptibility genes involved in complex disease. Indeed, in the modiWer gene context, multicenter studies are often required to collect large enough patient populations and there is thus a risk of allele frequency diVerences at random markers between centers. The clinical phenotypes are also more subtle than disease phenotypes and thus more subject to diVerences of evaluation between centers. To illustrate, consider a multicenter study of CF-associated lung disease where care practices diVer substantially between centers. Suppose that, in center A, patients show a milder form of the disease because of a better care practice and that moreover in the region where center A is located, there are also important allele frequency diVerences at one marker M, compared with the population in other regions. An association between marker M and lung disease severity might then be found, not because marker M is indeed involved but because the subgroup of patients with the mild forms will have an excess number of individuals from center A where allele frequencies at marker M are diVerent. If this example could appear a bit unrealistic, the recent availability of large samples of individuals genotyped for hundreds of thousands of markers has demonstrated that allele frequency diVerences between populations are a concern even within populations previously considered relatively homogeneous (Price et al. 2008; SteVens et al. 2006) .
New methods are currently being developed to account and correct for population stratiWcation in association studies (Epstein et al. 2007; Luca et al. 2008; Price et al. 2006 Price et al. , 2008 . These methods however have a cost in terms of power and might thus be diYcult to use when searching for modiWer genes. Another strategy consists in using familybased association tests with case-parent trio designs and the transmission disequilibrium test (TDT) (Spielman et al. 1993) . The advantage of this approach is that it tests for both linkage and association and thus ensures that any signiWcant results are not due to population admixture. The basic idea of these tests is to compare the alleles that parents do and do not transmit to their aVected children. Thus, the search for modiWer genes must examine whether or not there is a diVerence in parental transmissions according to the phenotypic categories of the aVected children. When the clinical phenotype is quantitative, diVerent methods have been proposed to test for associations with case-parent trio data. One is the quantitative TDT (QTDT) method, which relies on a variance component approach (Abecasis et al. 2000) . Alternatively, one might consider ordered TDT (OTDT), which, like the OSA method for linkage analysis, is based on the ordering of patients as a function of their quantitative phenotypic measures (Perdry et al. 2007 ). The aim, here, is to Wnd a critical value of the phenotypic measure that separates the trios into two groups with signiWcantly diVerent transmission rates. No assumption about the distribution of the phenotype in the population is made, contrary to the QTDT method, which requires normal distributions (Perdry et al. 2008) .
The sampling of case-parent trios might not be diYcult when studying diseases such as CF, which occur early in life, but this strategy has never been used to identify genetic modiWers.
Blind search: systematic genome-wide screens
The systematic screen, which consists in searching for the genetic factors involved in the phenotype of interest over the whole genome, was initially only possible for linkage testing. Maps of »400 microsatellite markers spaced an average of 10 centimorgans (cM) apart over the whole genome were available and could be used to perform linkage tests. This intermarker distance was enough to ensure good coverage of the genome when information about the co-segregation of phenotype and markers in families was used. A much denser map is needed, however, to test for association. Only very recently have such maps become available, through international projects such as HapMap (http://www.HapMap.org). Maps of single nucleotide polymorphisms (SNPs) are now available that provide good coverage of all common variations (those with a minor allele frequency of more than 5%) of the human genome. These maps include more than several hundred thousand markers that are available in chips (the new AVymetrix genome-wide SNP-array 6.0 includes 1.8 million genetic markers randomly chosen to cover the genome, and its competitor, the Illumina Human1 M BeadChip, allows genotyping of 1,072,820 markers, an important proportion of them located in genes). In recent years, these chips have been used to perform genome-wide association (GWA) studies to search for the genetic risk factors involved in complex diseases such as Type-2 diabetes, obesity, agerelated macular degeneration, Crohn disease, etc.
The huge number of markers tested makes it necessary to correct for multiple testing and thus to use very stringent criteria to conclude in a signiWcant association (see Appendix 1 for the multiple testing issue). Large samples of patients are thus necessary to detect a modiWer gene with a weak eVect. Figure 1 reports the required sample sizes to detect the association with a 80% power, on the assumption of a genetic risk factor with an eVect similar to that reported by Drumm et al. (2005) for the C509T polymorphism of the TGF 1 gene in CF-associated lung disease. Sample sizes are reported for both population-based and case-parent trio samples, and a Bonferroni correction for multiple testing is performed to ensure that the global type-one error rate is less than 5%. If 500,000 markers are tested to cover the whole genome, 1905 individuals with the phenotype of interest and 1905 without it will be required to ensure 80% power to detect the association. For modiWer genes, this means 3,810 patients with mutations involved in the Mendelian disease, a number completely unrealistic even for the most frequent Mendelian disorders. A case-parent trio design would require 1,914 patients and their parents. If the genotyping cost is higher than for the case-control design (3 N individuals instead of 2 N where N is the number of patients), it is interesting to note that the trio design oVers a non-negligible economy in terms of number of patients to collect (N instead of 2 N) and thus probably deserves more attention in modiWer gene studies.
Biology-driven approach: candidate gene tests
Instead of blind searches for modiWer genes over the whole genome, it may be wiser to focus on a more limited number Fig. 1 Sample sizes required to reach 80% power to detect an association when diVerent number of markers are tested. The total number of patients (white bars) or case-parent trios (black bars) required to reach a power of 80% are shown. A genetic factor is assumed, with an eVect similar to that of the C509T polymorphism of the TGF 1 gene in CFassociated lung disease: a 0.34 allele frequency acting recessively with an odds ratio of 2 (Drumm et al. 2005) . For the patient samples, it is assumed that the phenotype of interest is present in 50% of the individuals and absent in the remaining 50%. For the trio samples, all patients are assumed to have the phenotype. The program genetic power calculator (Purcell et al. 2003 ) was used with a Bonferroni correction for multiple testing 10 100 1,000 10,000 100,000 500,000
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Trios of carefully chosen genes, the so-called candidate genes. DiVerent approaches can be used to select these candidates. One might look Wrst at the genes involved in the same pathway as the primary mutation involved in the disease. For example, for familial hypercholesterolemia due to a mutation in the LDL receptor gene, genes of the lipoprotein pathway are good candidates. Alternatively, one might decide to focus on genes located in another pathway and involved in somewhat more indirect disease consequences. In CF, for example, candidate gene studies have considered genes involved in the inXammatory process. In hereditary hemochromatosis, a recent study showed that genes in the BMP pathway and involved in the expression of hepcidin, a peptide hormone produced by the liver that controls plasma iron concentration, might be promising candidates to explain the penetrance variability of the HFE p.C282Y mutation in homozygote carriers (Milet et al. 2007 ). Interestingly, the authors focused on an indirect measure of disease penetrance, the serum ferritin levels of C281Y homozygotes. This is the Wrst association detected between common variants in genes of the BMP pathway and iron burden. Further studies will need to determine if this is speciWc to p.C282Y carriers, by testing for the eVect of these variants on serum ferritin levels in the general population. Another example involves dilated cardiomyopathy, where candidate genes in diVerent pathways are being studied, in particular the beta-adrenergic pathway and the renin-angiotensin-aldosterone system. New approaches have also been used based on animal models, which allow a better control of the environment (Komajda and Charron 2004) . In a candidate gene or pathway approach, both linkage and association information may be used as it is important to recall that these two kinds of information are complementary and not redundant (Clerget-Darpoux and Bonaiti-Pellie 1992) .
Comparison of the diVerent strategies for modiWer gene identiWcation
The relative advantages of the strategies described above strongly depend on the genetic model underlying the clinical phenotype and there is not a single strategy that will be the best in all scenarios. Most often, the segregation analysis, which could provide information on this model, is not carried out and it is thus diYcult to know which will be the most promising strategy. It is very tempting to follow the trend from restricted candidate gene studies to extensive genome-wide scans, as in the genetic studies of common diseases. Recent genomewide association studies show that this strategy could work but it might also be disappointing, especially in modiWer gene studies where only limited samples are available. Also note that when new associations are described, replication studies of independent samples are essential. Guidelines for replicating genotype-phenotype associations have been proposed (Chanock et al. 2007 ), but they are diYcult to follow when looking for genetic modiWers since independent samples of suYcient sizes with the same phenotypic information as the initial sample may simply not exist. With the decreasing cost of genome-wide SNP arrays, it might be worthwhile to do whole genome chips and analyze only the regions suggested by this approach. This is true if the modiWer genes we are searching are well covered by the HapMap SNPs. However, recent studies show that a relatively high proportion of the common polymorphisms (minor allele frequency above 5%) detected in 500 genes through re-sequencing are not tagged by SNPs from HapMap, ranging from 50 to 20% depending on the population (Xu et al. 2007 ). The same study estimates that only approximately 30% of the nonsynonymous SNPs are in high LD with any HapMap SNP. This evaluation shows that to design special assays to study candidate genes and re-sequencing them in a subset of individuals remains a strategy to consider. A combined approach might also be promising where patients that are well characterized clinically are also characterized genetically by genotyping relatively dense SNP chips to constitute databases. The genome-wide information could then be used to rank candidate genes hat have been chosen based on biological knowledge on a priority list.
Systematic search of linkage on the genome lack power to detect the eVect of frequent alleles and replications are often diYcult. This is well illustrated by the example of meconium ileus in CF since a second genome-wide linkage study did not conWrm the linkage with the 19q13 region detected by (Zielenski et al. 1999 ) but found regions of suggestive linkage on chromosomes 4q35, 8p23 and 11q25 (Blackman et al. 2006 ). However it is important to keep in mind that, in other situations, linkage information may be useful both in detecting regions containing modiWer factors and in understanding the role of a genetic variant in the phenotypic variation. Clinicians should try to do their best to collect a maximum of familial information. This is particularly true when studying modiWer genes for which familial information might be more easily available than a large sample of unrelated patients as illustrated with HD in Venezuelan kindreds (Wexler et al. 2004 ). This information is crucial in the early steps of the study to evidence the role of genetic factors on the clinical phenotypes and try to determine which kind of genetic factors should be looked at. Should these genetic risks factors be rare mutations with strong eVect, linkage analysis on the families would then be the most powerful approach. But even in the case where a multifactorial-like model is more likely, the familial information should not be neglected as association and linkage provide complementary information both for evidencing the role of a candidate gene and to model its role on the clinical phenotype ClergetDarpoux and Elston 2007) .
Discussion
When the clinical expression of a monogenic disease varies considerably between patients, it is tempting to try to explain it by the eVect of some other genetic factors that modify the expression of the primary mutation, i.e., modiWer genes. However, before launching expensive and time-consuming genetic studies to identify these genetic modiWers, it is important to make sure that they really exist and that environmental factors or other mechanisms, such as genetic heterogeneity, do not suYce to explain this clinical variability. Investigators should also keep in mind that the eVect of modiWer genes might be very complex, as it is for the genetic risk factors involved in common diseases. Several genetic variants might be involved and may interact to modulate the eVect of the primary mutation. It is even possible that phenotypic variability may be explained not by the patients' modiWer genotypes but by their mothers' genotypes, as recently reported for the maternal Apo E genotype in Smith-Lemli-Opitz syndrome (Witsch-Baumgartner et al. 2008) .
Structural genomic variations, such as copy number variants (CNVs), might also be involved in the variability of penetrance and phenotypic expression in Mendelian diseases [for a review see (Beckmann et al. 2007) ]. Some but not all of these CNVs can be detected because of their linkage disequilibrium with common SNPs, and alternative strategies will need to be developed to test for associations with both CNVs and SNPs. Recent reports concerning the functional structure of the human genome show that other mechanisms, such as diVerences in transcription, may also explain disease expression variability and that the transcription domain of genes might extend very far beyond the usual regulatory sequences. These Wndings open up new perspectives for the search of cis-acting alleles (EncodeProject-Consortium 2007) .
An important issue in the search for modiWer genes is the choice of study phenotype. It is often possible to use diVerent variables to characterize disease expression, and studies of the heritability associated with them might help to choose the appropriate phenotype. The studies on CF and Huntington's disease illustrate this well. Nonetheless, it may be an impossible task for many Mendelian disorders because of the rarity of cases. The candidate genes may also dictate the choice of phenotype to look at, as in the example of hereditary hemochromatosis and the BMP pathway.
The search for modiWer genes is diYcult but worth being pursued-not only for the direct possibilities it might oVer to patients aVected by the disease but also for the better knowledge of biological pathways that will Xow indirectly from this quest. Although interest has shifted gradually from monogenic to more common multifactorial diseases, it is important to keep in mind that monogenic diseases represent a simpler model of diseases that teach us many things about the genetic basis of more complex diseases (Antonarakis and Beckmann 2006). The study of Mendelian disorders may also lead to the discovery of novel drug targets (Brinkman et al. 2006) .
Appendix: Multiple testing issues in association studies
When the number of markers tested increases, it is necessary to take into account the fact that multiple tests are performed. That is, if one deWnes as signiWcant any tests with a P value below 5%, and only one test is performed, the probability of incorrectly rejecting the null hypothesis and concluding in an association is 5%. If N tests are performed, this probability is increased proportionally: when N = 100 there will be on average Wve false-positive results and if N = 100,000 this number will be 5,000. To limit the proportion of false positives, corrections can be made for multiple testing. One of the most commonly is the Bonferroni correction. To ensure a global type-one error of 5% for N tests, it considers signiWcant only tests with a P value of less than 0.05/N. This correction is conservative when tests are not independent. Other less conservative corrections have been proposed, which take into account the correlation that may exist between markers through linkage disequilibrium (Li and Ji 2005; Nyholt 2004 ). Even after accounting for linkage disequilibrium, the signiWcance level for ensuring a genome-wide type 1 error of 5% remains on the order of 10 ¡7 .
